Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer

Findings from the adjuvant colon cancer endpoints data set

Joleen M Hubbard, David M. Thomas, Greg Yothers, Erin Green, Charles Blanke, Michael J. O'Connell, Roberto Labianca, Qian D Shi, Archie Bleyer, Aimery De Gramont, Daniel Sargent

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. Patients and Methods: Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. Results: One thousand seven hundred fifty-eight patients (5.2%) were younger than 40 years, 5,817 patients (17.3%) were younger than 50 years, and only 299 patients (0.9%) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. Conclusion: Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria.

Original languageEnglish (US)
Pages (from-to)2334-2339
Number of pages6
JournalJournal of Clinical Oncology
Volume30
Issue number19
DOIs
StatePublished - Jul 1 2012

Fingerprint

Adjuvant Chemotherapy
Colonic Neoplasms
Disease-Free Survival
Clinical Trials
Datasets
Survival
Recurrence
Therapeutics
Phase III Clinical Trials
Stomatitis
Leukopenia
Sex Characteristics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer : Findings from the adjuvant colon cancer endpoints data set. / Hubbard, Joleen M; Thomas, David M.; Yothers, Greg; Green, Erin; Blanke, Charles; O'Connell, Michael J.; Labianca, Roberto; Shi, Qian D; Bleyer, Archie; De Gramont, Aimery; Sargent, Daniel.

In: Journal of Clinical Oncology, Vol. 30, No. 19, 01.07.2012, p. 2334-2339.

Research output: Contribution to journalArticle

Hubbard, Joleen M ; Thomas, David M. ; Yothers, Greg ; Green, Erin ; Blanke, Charles ; O'Connell, Michael J. ; Labianca, Roberto ; Shi, Qian D ; Bleyer, Archie ; De Gramont, Aimery ; Sargent, Daniel. / Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer : Findings from the adjuvant colon cancer endpoints data set. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 19. pp. 2334-2339.
@article{0ea8b98b3b984950a04a9c3eed5410a6,
title = "Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: Findings from the adjuvant colon cancer endpoints data set",
abstract = "Purpose: Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. Patients and Methods: Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. Results: One thousand seven hundred fifty-eight patients (5.2{\%}) were younger than 40 years, 5,817 patients (17.3{\%}) were younger than 50 years, and only 299 patients (0.9{\%}) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. Conclusion: Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria.",
author = "Hubbard, {Joleen M} and Thomas, {David M.} and Greg Yothers and Erin Green and Charles Blanke and O'Connell, {Michael J.} and Roberto Labianca and Shi, {Qian D} and Archie Bleyer and {De Gramont}, Aimery and Daniel Sargent",
year = "2012",
month = "7",
day = "1",
doi = "10.1200/JCO.2011.41.1975",
language = "English (US)",
volume = "30",
pages = "2334--2339",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer

T2 - Findings from the adjuvant colon cancer endpoints data set

AU - Hubbard, Joleen M

AU - Thomas, David M.

AU - Yothers, Greg

AU - Green, Erin

AU - Blanke, Charles

AU - O'Connell, Michael J.

AU - Labianca, Roberto

AU - Shi, Qian D

AU - Bleyer, Archie

AU - De Gramont, Aimery

AU - Sargent, Daniel

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Purpose: Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. Patients and Methods: Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. Results: One thousand seven hundred fifty-eight patients (5.2%) were younger than 40 years, 5,817 patients (17.3%) were younger than 50 years, and only 299 patients (0.9%) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. Conclusion: Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria.

AB - Purpose: Limited data exist regarding the outcomes of adjuvant therapy in younger patients with stage II and III colon cancer. We examined disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and grade 3+ adverse events (AEs) in younger patients in the 33,574 patient Adjuvant Colon Cancer Endpoints Group data set. Patients and Methods: Individual patient data from 24 randomized phase III clinical trials were obtained for survival outcomes, which included 10 clinical trials for AE outcomes. Two age-based cutoff points were used to define younger patients: age younger than 40 years and younger than 50 years. Adjuvant therapy benefit analyses were limited to the nine clinical trials in which the investigational chemotherapeutic arm demonstrated benefit. Results: One thousand seven hundred fifty-eight patients (5.2%) were younger than 40 years, 5,817 patients (17.3%) were younger than 50 years, and only 299 patients (0.9%) were younger than 30 years. No meaningful differences in sex or stage were noted in younger versus older patients. Younger and older patients did not differ in RFI (age, < 40 years: hazard ratio [HR], 1.0; P = .62 and age < 50 years: HR, 1.02; P = .35). Younger patients (both cutoff points), had longer OS and DFS than older patients. In trials demonstrating adjuvant therapy benefit, similar DFS benefit was observed by age. Younger patients experienced less leukopenia and stomatitis, but more frequent nausea/vomiting. Conclusion: Among patients on clinical trials, younger and older patients with stage II and III colon cancer had similar RFI and adjuvant therapy benefit. Younger patients have longer OS and DFS, which is likely primarily because of fewer competing causes of death. Adjuvant therapy is beneficial for colon cancer in patients younger than 50 years who meet typical clinical trial eligibility criteria.

UR - http://www.scopus.com/inward/record.url?scp=84863993416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863993416&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.41.1975

DO - 10.1200/JCO.2011.41.1975

M3 - Article

VL - 30

SP - 2334

EP - 2339

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -